{"id":21663,"date":"2023-12-19T16:39:04","date_gmt":"2023-12-19T15:39:04","guid":{"rendered":"https:\/\/ggba.swiss\/machinemd-joins-top-five-in-dayone-health-4-0-accelerators-second-phase\/"},"modified":"2023-12-19T16:41:36","modified_gmt":"2023-12-19T15:41:36","slug":"machinemd-rejoint-les-cinq-finalistes-de-la-deuxieme-phase-de-laccelerateur-dayone-health-4-0","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/machinemd-rejoint-les-cinq-finalistes-de-la-deuxieme-phase-de-laccelerateur-dayone-health-4-0\/","title":{"rendered":"machineMD rejoint les cinq finalistes de la deuxi\u00e8me phase de l&rsquo;acc\u00e9l\u00e9rateur DayOne Health 4.0"},"content":{"rendered":"\n<p><a href=\"https:\/\/www.machinemd.com\/\">machineMD<\/a>, une spin-off de l&rsquo;<a href=\"https:\/\/www.insel.ch\/fr\/\">h\u00f4pital universitaire de Berne<\/a> d\u00e9sormais install\u00e9e au <a href=\"https:\/\/www.ssc.swiss\/\">Sitem Startup Club<\/a>, se distingue par son approche innovante du diagnostic des troubles neurologiques. Le dispositif r\u00e9volutionnaire de l&rsquo;entreprise, neos\u00ae, s&rsquo;appuie sur la technologie de la r\u00e9alit\u00e9 virtuelle pour r\u00e9aliser des examens neuro-ophtalmologiques standardis\u00e9s et automatis\u00e9s, am\u00e9liorant ainsi la pr\u00e9cision et la rapidit\u00e9 du diagnostic de maladies telles que les tumeurs c\u00e9r\u00e9brales et la scl\u00e9rose en plaques.<\/p>\n\n\n\n<p>Lors de la premi\u00e8re phase de l&rsquo;acc\u00e9l\u00e9rateur <a href=\"https:\/\/www.dayone.swiss\/\">DayOne Health 4.0<\/a> de 2023, qui s&rsquo;est d\u00e9roul\u00e9e de septembre \u00e0 novembre, machineMD a fait partie des quatre jeunes entreprises suisses s\u00e9lectionn\u00e9es parmi 109 candidatures provenant de 35 pays. La deuxi\u00e8me phase se concentre sur le d\u00e9veloppement des finalistes, en les pr\u00e9parant \u00e0 d&rsquo;\u00e9ventuelles collaborations et partenariats, en particulier avec des soci\u00e9t\u00e9s biopharmaceutiques.<\/p>\n\n\n\n<p>Le programme identifie des domaines cl\u00e9s tels que l&rsquo;optimisation de l&rsquo;identification des patients dans les essais cliniques, l&rsquo;am\u00e9lioration du d\u00e9veloppement clinique gr\u00e2ce aux donn\u00e9es et aux outils cliniques, la rationalisation des op\u00e9rations cliniques et l&rsquo;am\u00e9lioration de l&rsquo;exp\u00e9rience des patients afin de stimuler les r\u00e9sultats.<\/p>\n\n\n\n<p>Lorsque machineMD passera \u00e0 la deuxi\u00e8me phase, elle b\u00e9n\u00e9ficiera d&rsquo;un mentorat continu, d&rsquo;\u00e9changes d&rsquo;experts et d&rsquo;introductions aupr\u00e8s d&rsquo;acteurs essentiels de l&rsquo;\u00e9cosyst\u00e8me des soins de sant\u00e9. Ce soutien vise \u00e0 pr\u00e9parer les start-ups \u00e0 des collaborations \u00e0 la jonction avec l&rsquo;industrie pharmaceutique.<\/p>\n\n\n\n<p>Fond\u00e9e en 2019 par le Pr Mathias Abegg, MD, PhD, et une \u00e9quipe d&rsquo;entrepreneurs et d&rsquo;experts en dispositifs m\u00e9dicaux, machineMD a d\u00e9j\u00e0 r\u00e9alis\u00e9 des avanc\u00e9es significatives. Son dispositif phare, neos\u00ae, est reconnu comme dispositif m\u00e9dical de classe I en Suisse et au Royaume-Uni, et il est pr\u00e9vu de l&rsquo;introduire comme dispositif de classe II(a) aux \u00c9tats-Unis. Gr\u00e2ce \u00e0 sa technologie de pointe et au soutien de l&rsquo;acc\u00e9l\u00e9rateur DayOne Health 4.0, machineMD est bien plac\u00e9e pour \u00e9tendre son impact dans le domaine de la technologie m\u00e9dicale et au-del\u00e0.<\/p>\n\n\n\n<figure class=\"wp-block-embed aligncenter is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<iframe loading=\"lazy\" title=\"The Startup Ecosystem in the Canton of Bern\" width=\"500\" height=\"281\" src=\"https:\/\/www.youtube.com\/embed\/d6YxuxfFipc?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n<\/div><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>La start-up medtech bernoise machineMD a acc\u00e9d\u00e9 \u00e0 la deuxi\u00e8me phase du prestigieux acc\u00e9l\u00e9rateur DayOne Health 4.0, faisant ainsi partie des cinq finalistes sur un groupe initial de 15.<\/p>\n","protected":false},"author":6,"featured_media":21659,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1179,1148,1218,1163,1141,1158],"class_list":["post-21663","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-artificial-intelligence-fr-2","tag-financing-fr-2","tag-incubator-fr-2","tag-medtech-fr-2","tag-personalized-medicine-fr-2","tag-virtual-reality-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>machineMD rejoint la phase 2 de l&#039;acc\u00e9l\u00e9rateur DayOne Health 4.0<\/title>\n<meta name=\"description\" content=\"La start-up medtech bernoise machineMD a acc\u00e9d\u00e9 \u00e0 la deuxi\u00e8me phase du prestigieux DayOne Health 4.0 Accelerator.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/machinemd-rejoint-les-cinq-finalistes-de-la-deuxieme-phase-de-laccelerateur-dayone-health-4-0\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"machineMD rejoint la phase 2 de l&#039;acc\u00e9l\u00e9rateur DayOne Health 4.0\" \/>\n<meta property=\"og:description\" content=\"La start-up medtech bernoise machineMD a acc\u00e9d\u00e9 \u00e0 la deuxi\u00e8me phase du prestigieux DayOne Health 4.0 Accelerator.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/machinemd-rejoint-les-cinq-finalistes-de-la-deuxieme-phase-de-laccelerateur-dayone-health-4-0\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-19T15:39:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-12-19T15:41:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/machineMD-1180x811-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/machinemd-rejoint-les-cinq-finalistes-de-la-deuxieme-phase-de-laccelerateur-dayone-health-4-0\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/machinemd-rejoint-les-cinq-finalistes-de-la-deuxieme-phase-de-laccelerateur-dayone-health-4-0\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"machineMD rejoint les cinq finalistes de la deuxi\u00e8me phase de l&rsquo;acc\u00e9l\u00e9rateur DayOne Health 4.0\",\"datePublished\":\"2023-12-19T15:39:04+00:00\",\"dateModified\":\"2023-12-19T15:41:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/machinemd-rejoint-les-cinq-finalistes-de-la-deuxieme-phase-de-laccelerateur-dayone-health-4-0\/\"},\"wordCount\":387,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/machinemd-rejoint-les-cinq-finalistes-de-la-deuxieme-phase-de-laccelerateur-dayone-health-4-0\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/machineMD-1180x811-1.png\",\"keywords\":[\"Artificial Intelligence\",\"Financing\",\"Incubator\",\"Medtech\",\"Personalized Medicine\",\"Virtual Reality\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/machinemd-rejoint-les-cinq-finalistes-de-la-deuxieme-phase-de-laccelerateur-dayone-health-4-0\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/machinemd-rejoint-les-cinq-finalistes-de-la-deuxieme-phase-de-laccelerateur-dayone-health-4-0\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/machinemd-rejoint-les-cinq-finalistes-de-la-deuxieme-phase-de-laccelerateur-dayone-health-4-0\/\",\"name\":\"machineMD rejoint la phase 2 de l'acc\u00e9l\u00e9rateur DayOne Health 4.0\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/machinemd-rejoint-les-cinq-finalistes-de-la-deuxieme-phase-de-laccelerateur-dayone-health-4-0\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/machinemd-rejoint-les-cinq-finalistes-de-la-deuxieme-phase-de-laccelerateur-dayone-health-4-0\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/machineMD-1180x811-1.png\",\"datePublished\":\"2023-12-19T15:39:04+00:00\",\"dateModified\":\"2023-12-19T15:41:36+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"La start-up medtech bernoise machineMD a acc\u00e9d\u00e9 \u00e0 la deuxi\u00e8me phase du prestigieux DayOne Health 4.0 Accelerator.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/machinemd-rejoint-les-cinq-finalistes-de-la-deuxieme-phase-de-laccelerateur-dayone-health-4-0\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/machinemd-rejoint-les-cinq-finalistes-de-la-deuxieme-phase-de-laccelerateur-dayone-health-4-0\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/machinemd-rejoint-les-cinq-finalistes-de-la-deuxieme-phase-de-laccelerateur-dayone-health-4-0\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/machineMD-1180x811-1.png\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/machineMD-1180x811-1.png\",\"width\":1180,\"height\":811,\"caption\":\"L'acc\u00e9l\u00e9rateur DayOne Health 4.0, connu pour encourager les start-ups de sant\u00e9 num\u00e9rique en phase initiale ou interm\u00e9diaire, offre un soutien complet comprenant un coaching personnalis\u00e9, des contributions d'experts et l'acc\u00e8s \u00e0 des acteurs cl\u00e9s du secteur de la sant\u00e9. | \u00a9 machineMD\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/machinemd-rejoint-les-cinq-finalistes-de-la-deuxieme-phase-de-laccelerateur-dayone-health-4-0\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"machineMD rejoint les cinq finalistes de la deuxi\u00e8me phase de l&#8217;acc\u00e9l\u00e9rateur DayOne Health 4.0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"machineMD rejoint la phase 2 de l'acc\u00e9l\u00e9rateur DayOne Health 4.0","description":"La start-up medtech bernoise machineMD a acc\u00e9d\u00e9 \u00e0 la deuxi\u00e8me phase du prestigieux DayOne Health 4.0 Accelerator.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/machinemd-rejoint-les-cinq-finalistes-de-la-deuxieme-phase-de-laccelerateur-dayone-health-4-0\/","og_locale":"fr_FR","og_type":"article","og_title":"machineMD rejoint la phase 2 de l'acc\u00e9l\u00e9rateur DayOne Health 4.0","og_description":"La start-up medtech bernoise machineMD a acc\u00e9d\u00e9 \u00e0 la deuxi\u00e8me phase du prestigieux DayOne Health 4.0 Accelerator.","og_url":"https:\/\/ggba.swiss\/fr\/machinemd-rejoint-les-cinq-finalistes-de-la-deuxieme-phase-de-laccelerateur-dayone-health-4-0\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2023-12-19T15:39:04+00:00","article_modified_time":"2023-12-19T15:41:36+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/machineMD-1180x811-1.png","type":"image\/png"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/machinemd-rejoint-les-cinq-finalistes-de-la-deuxieme-phase-de-laccelerateur-dayone-health-4-0\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/machinemd-rejoint-les-cinq-finalistes-de-la-deuxieme-phase-de-laccelerateur-dayone-health-4-0\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"machineMD rejoint les cinq finalistes de la deuxi\u00e8me phase de l&rsquo;acc\u00e9l\u00e9rateur DayOne Health 4.0","datePublished":"2023-12-19T15:39:04+00:00","dateModified":"2023-12-19T15:41:36+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/machinemd-rejoint-les-cinq-finalistes-de-la-deuxieme-phase-de-laccelerateur-dayone-health-4-0\/"},"wordCount":387,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/machinemd-rejoint-les-cinq-finalistes-de-la-deuxieme-phase-de-laccelerateur-dayone-health-4-0\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/machineMD-1180x811-1.png","keywords":["Artificial Intelligence","Financing","Incubator","Medtech","Personalized Medicine","Virtual Reality"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/machinemd-rejoint-les-cinq-finalistes-de-la-deuxieme-phase-de-laccelerateur-dayone-health-4-0\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/machinemd-rejoint-les-cinq-finalistes-de-la-deuxieme-phase-de-laccelerateur-dayone-health-4-0\/","url":"https:\/\/ggba.swiss\/fr\/machinemd-rejoint-les-cinq-finalistes-de-la-deuxieme-phase-de-laccelerateur-dayone-health-4-0\/","name":"machineMD rejoint la phase 2 de l'acc\u00e9l\u00e9rateur DayOne Health 4.0","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/machinemd-rejoint-les-cinq-finalistes-de-la-deuxieme-phase-de-laccelerateur-dayone-health-4-0\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/machinemd-rejoint-les-cinq-finalistes-de-la-deuxieme-phase-de-laccelerateur-dayone-health-4-0\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/machineMD-1180x811-1.png","datePublished":"2023-12-19T15:39:04+00:00","dateModified":"2023-12-19T15:41:36+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"La start-up medtech bernoise machineMD a acc\u00e9d\u00e9 \u00e0 la deuxi\u00e8me phase du prestigieux DayOne Health 4.0 Accelerator.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/machinemd-rejoint-les-cinq-finalistes-de-la-deuxieme-phase-de-laccelerateur-dayone-health-4-0\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/machinemd-rejoint-les-cinq-finalistes-de-la-deuxieme-phase-de-laccelerateur-dayone-health-4-0\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/machinemd-rejoint-les-cinq-finalistes-de-la-deuxieme-phase-de-laccelerateur-dayone-health-4-0\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/machineMD-1180x811-1.png","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/machineMD-1180x811-1.png","width":1180,"height":811,"caption":"L'acc\u00e9l\u00e9rateur DayOne Health 4.0, connu pour encourager les start-ups de sant\u00e9 num\u00e9rique en phase initiale ou interm\u00e9diaire, offre un soutien complet comprenant un coaching personnalis\u00e9, des contributions d'experts et l'acc\u00e8s \u00e0 des acteurs cl\u00e9s du secteur de la sant\u00e9. | \u00a9 machineMD"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/machinemd-rejoint-les-cinq-finalistes-de-la-deuxieme-phase-de-laccelerateur-dayone-health-4-0\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"machineMD rejoint les cinq finalistes de la deuxi\u00e8me phase de l&#8217;acc\u00e9l\u00e9rateur DayOne Health 4.0"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/21663","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=21663"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/21663\/revisions"}],"predecessor-version":[{"id":21665,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/21663\/revisions\/21665"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/21659"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=21663"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=21663"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=21663"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}